$TSHA
Taysha Gene Therapies, Inc.

2021 Q2 Form 10-Q Financial Statement

#000156459021044462 Filed on August 16, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.13M $1.018M
YoY Change 894.99%
% of Gross Profit
Research & Development $30.64M $3.062M $3.000M
YoY Change 900.75%
% of Gross Profit
Depreciation & Amortization $85.00K $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $40.77M $4.010M $5.584M
YoY Change 916.76%
Operating Profit -$40.77M -$4.010M -$5.584M
YoY Change 916.76%
Interest Expense $194.0K -$27.00K $27.00K
YoY Change -818.52%
% of Operating Profit
Other Income/Expense, Net -$154.0K -$17.21M $153.0K
YoY Change -99.11%
Pretax Income -$40.93M -$26.65M
YoY Change 53.56%
Income Tax
% Of Pretax Income
Net Earnings -$40.93M -$21.22M -$5.431M
YoY Change 92.87%
Net Earnings / Revenue
Basic Earnings Per Share -$1.09
Diluted Earnings Per Share -$1.09 -$772.0K
COMMON SHARES
Basic Shares Outstanding 37.48M
Diluted Shares Outstanding 37.48M

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $197.4M $11.20M
YoY Change 1662.23%
Cash & Equivalents $197.4M $11.20M $16.33M
Short-Term Investments
Other Short-Term Assets $1.014M $100.0K
YoY Change 914.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $207.3M $11.30M
YoY Change 1734.53%
LONG-TERM ASSETS
Property, Plant & Equipment $33.87M $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $691.0K
YoY Change
Total Long-Term Assets $34.56M $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $207.3M $11.30M
Total Long-Term Assets $34.56M $0.00
Total Assets $241.9M $11.30M
YoY Change 2040.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.355M $1.300M
YoY Change 388.85%
Accrued Expenses $22.04M $1.600M
YoY Change 1277.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $100.0K
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $28.39M $20.10M
YoY Change 41.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $765.0K
YoY Change
Total Long-Term Liabilities $765.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $28.39M $20.10M
Total Long-Term Liabilities $765.0K $0.00
Total Liabilities $55.37M $20.10M
YoY Change 175.45%
SHAREHOLDERS EQUITY
Retained Earnings -$134.1M
YoY Change
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $186.5M -$26.79M -$5.566M
YoY Change
Total Liabilities & Shareholders Equity $241.9M $11.30M
YoY Change 2040.35%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income -$40.93M -$21.22M -$5.431M
YoY Change 92.87%
Depreciation, Depletion And Amortization $85.00K $0.00 $0.00
YoY Change
Cash From Operating Activities -$22.81M -$4.170M -$1.699M
YoY Change 447.03%
INVESTING ACTIVITIES
Capital Expenditures -$3.002M $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$5.500M -$3.000M
YoY Change 83.33%
Cash From Investing Activities -$8.502M -$3.000M $0.00
YoY Change 183.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 18.37M 18.03M
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -22.81M -4.170M -1.699M
Cash From Investing Activities -8.502M -3.000M 0.000
Cash From Financing Activities 0.000 18.37M 18.03M
Net Change In Cash -31.31M 11.20M 16.33M
YoY Change -379.58%
FREE CASH FLOW
Cash From Operating Activities -$22.81M -$4.170M -$1.699M
Capital Expenditures -$3.002M $0.00
Free Cash Flow -$19.81M -$1.699M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54497000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8576000
CY2020Q4 us-gaap Deferred Costs Leasing Net Noncurrent
DeferredCostsLeasingNetNoncurrent
715000
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1994000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5135000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7129000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
765000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
450000
CY2021Q2 us-gaap Liabilities
Liabilities
55365000
CY2020Q4 us-gaap Liabilities
Liabilities
7579000
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
320571000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
312428000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-134076000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61126000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
186495000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
251302000
CY2021Q2 us-gaap Deferred Costs Leasing Net Noncurrent
DeferredCostsLeasingNetNoncurrent
691000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33867000
CY2021Q2 tsha Build To Suit Lease Liability
BuildToSuitLeaseLiability
26209000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
241860000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10129000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
948000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4010000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
222872000
us-gaap Operating Expenses
OperatingExpenses
9594000
us-gaap Operating Income Loss
OperatingIncomeLoss
-72862000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4549000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38391165
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38391165
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37761435
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37761435
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
258881000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30643000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3062000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9594000
us-gaap Interest Expense
InterestExpense
194000
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
1645000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11200000
tsha Allocation Of Preferred Stock Tranche Liability
AllocationOfPreferredStockTrancheLiability
1050000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
106000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18365000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1018000
us-gaap Operating Expenses
OperatingExpenses
72862000
us-gaap Interest Expense
InterestExpense
27000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-88000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17057000
us-gaap Net Income Loss
NetIncomeLoss
-72950000
us-gaap Net Income Loss
NetIncomeLoss
-26651000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.96
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.45
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37237115
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10894999
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8143000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
40000
CY2021Q2 us-gaap Interest Expense
InterestExpense
194000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
40772000
us-gaap Net Income Loss
NetIncomeLoss
-72950000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
4010000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-40772000
CY2020Q2 tsha Change In Fair Value Of Preferred Stock Tranche Liability
ChangeInFairValueOfPreferredStockTrancheLiability
-17210000
tsha Change In Fair Value Of Preferred Stock Tranche Liability
ChangeInFairValueOfPreferredStockTrancheLiability
-17030000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-154000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17210000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-40926000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-21220000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.09
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.95
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37479164
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10894999
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-40926000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
186495000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-5566000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-21220000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-26786000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
251302000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
186495000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-135000
tsha Temporary Equity Stock Issuance Of Preferred Stock Tranche Liability
TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability
1050000
us-gaap Net Income Loss
NetIncomeLoss
-26651000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-26786000
us-gaap Profit Loss
ProfitLoss
-72950000
us-gaap Profit Loss
ProfitLoss
-26651000
us-gaap Depreciation
Depreciation
117000
tsha Change In Fair Value Of Preferred Stock Tranche Liability
ChangeInFairValueOfPreferredStockTrancheLiability
-17030000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
5500000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
3000000
us-gaap Share Based Compensation
ShareBasedCompensation
8143000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-194000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3282000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2382000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1237000
tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
15053000
tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
1214000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-8000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
14000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44851000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4165000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
5500000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
3000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3532000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9032000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3000000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
18600000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
263000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1673000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18365000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-53883000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11200000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
251253000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
197370000
us-gaap Interest Paid Net
InterestPaidNet
27000
tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
3308000
tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
19000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
606000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
26250000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
90000
tsha Reclassification Of Preferred Stock Liability
ReclassificationOfPreferredStockLiability
904000
us-gaap Stock Issued1
StockIssued1
177000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2020-02-13
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-134100000
CY2021Q2 us-gaap Cash
Cash
197400000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates and assumptions in the Company’s financial statements relate to the determination of the fair value of the common stock prior to the IPO (as an input into stock-based compensation), estimating preclinical manufacturing accruals and accrued or prepaid research and development expenses, and the valuation of the preferred stock tranche liability. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. In response to the ongoing and rapidly evolving COVID-19 pandemic, management considered the impact of the estimated economic implications on the Company’s critical and significant accounting estimates, including assessment of impairment of long-lived assets.</p>
CY2020Q4 tsha Prepaid Bonus
PrepaidBonus
409000
CY2021Q2 us-gaap Prepaid Insurance
PrepaidInsurance
826000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2480000
CY2021Q2 us-gaap Depreciation
Depreciation
85000
us-gaap Depreciation
Depreciation
117000
CY2020Q2 us-gaap Depreciation
Depreciation
0
CY2021Q2 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
6716000
CY2020Q4 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
2462000
CY2021Q2 tsha Prepaid Bonus
PrepaidBonus
1192000
CY2021Q2 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
184000
CY2020Q4 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
944000
CY2021Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1014000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
331000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9932000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6626000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33993000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
296000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
126000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33867000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
287000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-40926000
us-gaap Depreciation
Depreciation
0
CY2021Q2 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
14508000
CY2020Q4 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2106000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3210000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1766000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1372000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
999000
CY2021Q2 tsha Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
1309000
CY2020Q4 tsha Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
173000
CY2021Q2 tsha Accrued Clinical Trial Current
AccruedClinicalTrialCurrent
959000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
678000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
91000
CY2021Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
22036000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5135000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
32685000
CY2020Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
15647052
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 tsha Preferred Stock Tranche Liability
PreferredStockTrancheLiability
1100000
CY2020Q2 tsha Change In Fair Value Of Preferred Stock Tranche Liability
ChangeInFairValueOfPreferredStockTrancheLiability
17000000.0
CY2020Q2 tsha Mile Stone Shares Issued
MileStoneSharesIssued
200000
CY2020Q2 tsha Amount Reclassified To Convertible Preferred Stock
AmountReclassifiedToConvertiblePreferredStock
900000
CY2020Q2 tsha Mile Stone Shares Issued
MileStoneSharesIssued
200000
CY2020Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
7.52
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21220000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-72950000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26651000
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37479164
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4549000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8143000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10894999
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37237115
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10894999
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.09
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.95
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.96
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.45
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5737044
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001564590-21-044462-index-headers.html Edgar Link pending
0001564590-21-044462-index.html Edgar Link pending
0001564590-21-044462.txt Edgar Link pending
0001564590-21-044462-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g3dyckr3udth000001.jpg Edgar Link pending
g3dyckr3udth000002.jpg Edgar Link pending
g3dyckr3udth000003.jpg Edgar Link pending
g3dyckr3udth000004.jpg Edgar Link pending
g3dyckr3udth000005.jpg Edgar Link pending
g3dyckr3udth000006.jpg Edgar Link pending
g3dyckr3udth000007.jpg Edgar Link pending
g3dyckr3udth000008.jpg Edgar Link pending
g3dyckr3udth000009.jpg Edgar Link pending
g3dyckr3udth000010.jpg Edgar Link pending
g3dyckr3udth000011.jpg Edgar Link pending
g3dyckr3udth000012.jpg Edgar Link pending
g3dyckr3udth000013.jpg Edgar Link pending
g3dyckr3udth000014.jpg Edgar Link pending
g3dyckr3udth000015.jpg Edgar Link pending
g3dyckr3udth000016.jpg Edgar Link pending
g3dyckr3udth000017.jpg Edgar Link pending
g3dyckr3udth000018.jpg Edgar Link pending
g3dyckr3udth000019.jpg Edgar Link pending
g3dyckr3udth000020.jpg Edgar Link pending
g3dyckr3udth000021.jpg Edgar Link pending
g3dyckr3udth000022.jpg Edgar Link pending
g3dyckr3udth000023.jpg Edgar Link pending
g3dyckr3udth000024.jpg Edgar Link pending
g3dyckr3udth000025.jpg Edgar Link pending
g3dyckr3udth000026.jpg Edgar Link pending
g3dyckr3udth000027.jpg Edgar Link pending
g3dyckr3udth000028.jpg Edgar Link pending
g3dyckr3udth000029.jpg Edgar Link pending
g3dyckr3udth000030.jpg Edgar Link pending
g3dyckr3udth000031.jpg Edgar Link pending
g3dyckr3udth000032.jpg Edgar Link pending
g3dyckr3udth000033.jpg Edgar Link pending
g3dyckr3udth000034.jpg Edgar Link pending
g3dyckr3udth000035.jpg Edgar Link pending
g3dyckr3udth000036.jpg Edgar Link pending
g3dyckr3udth000037.jpg Edgar Link pending
g3dyckr3udth000038.jpg Edgar Link pending
g3dyckr3udth000039.jpg Edgar Link pending
g3dyckr3udth000040.jpg Edgar Link pending
g3dyckr3udth000041.jpg Edgar Link pending
g3dyckr3udth000042.jpg Edgar Link pending
gpujbzzweac5000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tsha-10q_20210630.htm Edgar Link pending
tsha-10q_20210630_htm.xml Edgar Link completed
tsha-20210630.xsd Edgar Link pending
tsha-20210630_cal.xml Edgar Link unprocessable
tsha-20210630_def.xml Edgar Link unprocessable
tsha-20210630_lab.xml Edgar Link unprocessable
tsha-20210630_pre.xml Edgar Link unprocessable
tsha-ex101_249.htm Edgar Link pending
tsha-ex102_932.htm Edgar Link pending
tsha-ex311_7.htm Edgar Link pending
tsha-ex312_6.htm Edgar Link pending
tsha-ex321_9.htm Edgar Link pending
tsha-ex322_8.htm Edgar Link pending